Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2
- 1 May 1997
- journal article
- Published by Elsevier in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Vol. 376 (1-2) , 135-142
- https://doi.org/10.1016/s0027-5107(97)00036-5
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Metabolic polymorphism affecting DNA binding and excretion of carcinogens in humansPharmacogenetics, 1995
- Functional significance of different human CYPlAl genotypesCarcinogenesis: Integrative Cancer Research, 1994
- Relationship between genotype and function of the human CYP1A1 geneJournal of Toxicology and Environmental Health, 1993
- Genetic Risk and Carcinogen Exposure: a Common Inherited Defect of the Carcinogen-Metabolism Gene Glutathione S-Transferase M1 (GSTM1) That Increases Susceptibility to Bladder CancerJNCI Journal of the National Cancer Institute, 1993
- Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolitesPharmacogenetics, 1992
- N-acetylation pharmacogenetics: a gene deletion causes absence of arylamine N-acetyltransferase in liver of slow acetylator rabbits.Proceedings of the National Academy of Sciences, 1989
- Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.Proceedings of the National Academy of Sciences, 1989
- The contribution of genetically determined oxidation status to inter‐ individual variation in phenacetin disposition.British Journal of Clinical Pharmacology, 1983
- Intraindividual variation in drug dispositionClinical Pharmacology & Therapeutics, 1979
- A general method for isolation of high molecular weight DNA from eukaryotesNucleic Acids Research, 1976